Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYD88 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials Front Oncol - 2 weeks (New C3) methotrexate Sensitive : C3 Front Oncol - 2wk	methotrexate Sensitive: C3 – Early Trials Front Oncol - 2 weeks methotrexate Sensitive : C3 Front Oncol - 2 weeks - (New C3)
MYD88 mutation	Lymphoma	MYD88 mutation	Lymphoma	rituximab + orelabrutinib Sensitive: C3 – Early Trials ASH 2022 - 3 weeks (New C3) rituximab + orelabrutinib Sensitive : C3 ASH 2022 - 3wk	rituximab + orelabrutinib Sensitive: C3 – Early Trials ASH 2022 - 3 weeks rituximab + orelabrutinib Sensitive : C3 ASH 2022 - 3 weeks - (New C3)
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 mutation	Marginal Zone Lymphoma	MYD88 mutation	Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 mutation	Marginal Zone Lymphoma	MYD88 mutation	Marginal Zone Lymphoma	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D